Edwards Lifesciences (WBO:EWLS) Current Accrued Expense: €517 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:EWLS Edwards Lifesciences Corp WBO:EWLS
95 GF Score
Price €78.54
GF Value €81.99
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Current Accrued Expense?

Edwards Lifesciences WBO:EWLS -1.38% 95 Current Accrued Expense is €517 Mil as of Jun. 2026. GuruFocus rates WBO:EWLS with a GF Score™ of 95/100 and a GF Value™ of €81.99 (Fairly Valued). The stock has 5 warning signs investors should review.

Edwards Lifesciences's Current Accrued Expense for the quarter that ended in Jun. 2026 was €517 Mil.

Edwards Lifesciences's quarterly Current Accrued Expense declined from Dec. 2025 (€610 Mil) to Mar. 2026 (€524 Mil) and declined from Mar. 2026 (€524 Mil) to Jun. 2026 (€517 Mil).

Edwards Lifesciences's annual Current Accrued Expense increased from Dec. 2023 (€320 Mil) to Dec. 2024 (€395 Mil) and increased from Dec. 2024 (€395 Mil) to Dec. 2025 (€610 Mil).

Edwards Lifesciences Current Accrued Expense Related Terms

Edwards Lifesciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Current Accrued Expense Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 318.69 371.75 320.22 394.70 610.01

Edwards Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 406.28 512.05 610.01 524.19 517.15
WBO:EWLS
95GF Score
Edwards Lifesciences Corp WBO:EWLS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €517 Mil mean?
Edwards Lifesciences (WBO:EWLS) has a Current Accrued Expense of €517 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Current Accrued Expense too high?
Edwards Lifesciences' current Current Accrued Expense is €517 Mil. Overall, Edwards Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Current Accrued Expense compare to BSX and DXCM?
Edwards Lifesciences' Current Accrued Expense of €517 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Current Accrued Expense is €517 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €81.99, compared to a current price of €78.54 — trading 4.2% below its estimated fair value. The current Current Accrued Expense is €517 Mil. Edwards Lifesciences' overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current Current Accrued Expense is €517 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €78.54 is trading 4.2% below its estimated GF Value™ of €81.99. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for WBO:EWLS:

  • Current Accrued Expense: €517 Mil
  • GF Value™: €81.99 vs. price of €78.54 (4.2% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
95GF Score

Get the complete analysis for WBO:EWLS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.54
Price
€81.99
GF Value